Humanin restores metabolic hormone homeostasis of leptin, ghrelin, irisin, and asprosin in STZ-induced diabetic mice
Background
The global prevalence of Diabetes mellitus (DM) is closely linked to mitochondrial dysfunction, which severely disrupts cellular energy metabolism and perturbs hormonal homeostasis. Current treatments often target glucose regulation but may not fully address the complex interplay of metabolic hormones. Humanin (HN), a 24-amino acid peptide encoded within the mitochondrial genome, has shown cytoprotective and metabolic regulatory properties. However, its specific role in coordinating key metabolic hormone networks, such as leptin, ghrelin, irisin, and asprosin, under diabetic conditions has remained poorly understood, representing a critical gap this study addresses.
Study Design
Researchers investigated humanin's effects on metabolic hormones in a streptozotocin (STZ)-induced diabetic mouse model. Forty male mice were divided into four groups (n = 10 each): control, HN (4 mg/kg/day), STZ, and STZ + HN. Humanin was administered intraperitoneally (IP) for 15 consecutive days. Serum levels of leptin, asprosin, irisin, and ghrelin were quantified using enzyme-linked immunosorbent assay (ELISA). Data analysis involved one-way ANOVA followed by Tukey's post hoc test to compare group differences and assess hormonal changes.
Results
STZ-induced diabetes significantly disrupted metabolic hormone balance, characterized by decreased leptin and irisin levels and increased asprosin concentrations. Repeated HN treatment effectively restored leptin levels in diabetic mice. Furthermore, HN significantly suppressed the elevated asprosin concentrations observed in STZ-diabetic animals. While irisin levels showed a relative increase compared to the untreated STZ group, they were not fully normalized to control levels. Notably, ghrelin levels were significantly elevated in HN-treated diabetic mice compared to untreated STZ animals, indicating a broader impact on appetite-regulating hormones. These findings highlight Humanin's capacity to modulate multiple endocrine signals.
Humanin exerts an integrative, multi-hormonal regulatory effect, supporting the restoration of metabolic and endocrine homeostasis under diabetic conditions.
Key Findings
- STZ-induced diabetes significantly decreased leptin and irisin levels.
- STZ-induced diabetes significantly increased asprosin concentrations.
- Humanin treatment effectively restored leptin levels in diabetic mice.
- Humanin treatment suppressed elevated asprosin concentrations.
- Humanin significantly elevated ghrelin levels in diabetic mice.
Why It Matters
This study suggests that Humanin could offer a novel therapeutic strategy for managing Diabetes mellitus by addressing the underlying hormonal dysregulation beyond just glucose control. For peptide users and biohackers, these findings underscore Humanin's potential as a metabolic modulator, particularly for those concerned with mitochondrial health and endocrine balance. While this is a preclinical animal study, the consistent 4 mg/kg/day IP × 15 days protocol provides initial insights into potential dosing strategies. Humanin's ability to restore multiple key metabolic hormones, including leptin and ghrelin, points towards a comprehensive approach to improving metabolic health, potentially influencing appetite, energy expenditure, and insulin sensitivity. Further research is needed to translate these findings into human protocols.
humanin
diabetes
metabolic-hormones
leptin
ghrelin
irisin